Breaking News Headlines Today | Ground News

See every side of every news story

cancernetwork.com image

News from cancernetwork.com

Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Science · Shanghai

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

50% Center coverage: 28 sources

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-stimulating…See the Story

Cancer mortality drops 34% as treatments and early detection improve

Cancer · United States

Cancer mortality drops 34% as treatments and early detection improve

50% Center coverage: 6 sources

The 2026 cancer statistics reveal improved survival rates but highlight persistent inequities in cancer incidence and mortality across different populations.See the Story

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Culver City · Culver City

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

100% Center coverage: 2 sources

CULVER CITY, Calif.--(BUSINESS WIRE)--Jan 16, 2026-See the Story

Breaking News Topics Related to cancernetwork.com